IDXX as reported
Idexx Laboratories reported $4.55B of revenue over the trailing twelve months, +13% on the year before. 11 reported series are charted on this page, each one as filed.
$4.55B
Revenue, trailing twelve months · to Q2 2026 · +13% against the twelve months before
- Net Income
- $1.14B
Net Income · +16% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $1.25B
Free Cash Flow · +60% year on year · trailing twelve months to Q2 2026
- Op Margin
- 32%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $4.55B | +13% | Q2 2026 |
| Net Income | $1.14B | +16% | Q2 2026 |
| EPS | $14.23 | +18% | Q2 2026 |
| Gross Margin | 62% | n/a | Q2 2026 |
| Op Margin | 32% | n/a | Q2 2026 |
| Net Margin | 25% | n/a | Q2 2026 |
| ROE | 68% | n/a | Q2 2026 |
| ROA | 32% | n/a | Q2 2026 |
| ROIC | 50% | n/a | Q2 2026 |
| Free Cash Flow | $1.25B | +60% | Q2 2026 |
| P/E | 38.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Idexx Laboratories (IDXX) - Revenue & ProfitRevenue & ProfitIdexx Laboratories (IDXX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Diagnostics & Research
Ranks #10 of 29 by Smart Score